Abstract:
Monoclonal antibodies which specifically bind to putative Hepatitis C Virus (HCV) envelope region. Also provided are hybridoma cell lines which secrete these monoclonal antibodies, methods for using these monoclonal antibodies, and assay kits which contain these monoclonal antibodies.
Abstract:
A means for determining the effectiveness of interferon therapy in individuals who are infected with Hepatitis C Virus (HCV) and are receiving such therapy. Monitoring the level of anti-HCV IgM and/or anti-GOR IgG provide means for establishing whether or not the infected patient is responding to interferon therapy; such monitoring is especially useful for patients diagnosed with chronic acute HCV infections.
Abstract:
An assay for determining the presence of HCV IgM in a test sample. A test sample is contacted with at least one HCV antigen, incubated to form antigen/antibody complexes, and then contacted with an indicator reagent in order to produce a detectable signal. The amount of HCV IgM present in the test sample is proportional to the signal generated. The assay also can include the step of contacting the complexes with an enhancer compound prior to the use of an indicator reagent. Also provided is a test kit useful for performing the assay of the invention.
Abstract:
Mutant Hepatitis B Virus (HBV) nucleic acid sequences useful for a variety of diagnostic and therapeutic applications, kits for using the HBV nucleic acid sequences, HBV immunogenic particles, and a method for producing antibodies to HBV. Also provided are methods for producing antibodies, polyclonal or monoclonal, from the HBV nucleic acid sequences.
Abstract:
Monoclonal antibodies which specifically bind to either Hepatitis C Virus C-100 protein, Hepatitis C Virus 33C protein and Hepatits C Virus CORE protein, and hybridomas which produce these monoclonal antibodies. Also provided are methods for using these monoclonal antibodies and assay kits containing these antibodies.
Abstract:
A means for determining the effectiveness of interferon therapy in individuals who are infected with Hepatitis C Virus (HCV) and are receiving such therapy. Monitoring the level of anti-HCV IgM and/or anti-GOR IgG provide means for establishing whether or not the infected patient is responding to interferon therapy; such monitoring is especially useful for patients diagnosed with chronic acute HCV infections.
Abstract:
Anticorps monoclonaux se liant spécifiquement à la protéine C-100 du virus de l'hépatite C, à la protéine 33-C du virus de l'hépatite C ainsi qu'à la protéine core (noyau) du virus de l'hépatite C, et hybridomes produisant ces anticorps monoclonaux. L'invention concerne également des procédés d'utilisation de ces anticorps monoclonaux ainsi que des matériels de dosage contenant ces anticorps.
Abstract:
L'invention se rapporte à des anticorps monoclonaux qui se lient spécifiquement aux régions d'enveloppe putatives du virus de l'hépatite C (VHC). L'invention décrit également des lignées cellulaires d'hybridomes qui sécrètent ces anticorps monoclonaux, des procédés d'utilisation de ces anticorps monoclonaux, et des kits d'analyse les contenant.
Abstract:
Monoclonal antibodies which specifically bind to either Hepatitis C Virus C-100 protein, Hepatitis C Virus 33C protein and Hepatits C Virus CORE protein, and hybridomas which produce these monoclonal antibodies. Also provided are methods for using these monoclonal antibodies and assay kits containing these antibodies.
Abstract:
Monoclonal antibodies which specifically bind to putative Hepatitis C Virus (HCV) envelope region. Also provided are hybridoma cell lines which secrete these monoclonal antibodies, methods for using these monoclonal antibodies, and assay kits which contain these monoclonal antibodies.